APOE gene linked to Alzheimer disease may protect retinal ganglion cells, study finds
August 22nd 2022APOE4 gene associated with Alzheimer’s disease risk was found to protect mice from glaucoma. Research team also prevented retinal ganglion cell death by blocking the APOE signaling pathway, pointing to a potential treatment strategy for glaucoma.
Read More
Retina may provide clues to the severity of multiple sclerosis
August 17th 2022Researchers at the Medical University of Vienna are focusing on how the retina can be used as a prognostic marker. Analyses revealed that retinal layer thinning as a result of an MS relapse predicts the severity of future relapses and the likelihood of disability.
Read More
With the support of Harrington Discovery Institute at University Hospitals, an ophthalmic therapeutic dubbed KIO-301, initially developed by Richard Kramer, PhD, at the University of California, Berkeley (UCB), has successfully been granted approval to start a Phase 1b, first-in-human clinical trial.
Read More
Kodiak Sciences Inc. announced that its BEACON Phase 3 study of tarcocimab, its novel antibody biopolymer conjugate, met the primary endpoint of non-inferior change from baseline in visual acuity at week 24 compared to aflibercept in patients with macular edema due to retinal vein occlusion.
Read More
Research aims to regenerate photoreceptors cells via stem cell-based therapy
August 7th 2022A multi-institutional effort led by researchers at the University of Pennsylvania is taking steps to develop an effective technique to regenerate photoreceptors cells and restore sight in patients with vision disorders.
Read More
First patient dosed in Phase 2 DAVIO trial for wet AMD
August 4th 2022According to EyePoint Pharmaceuticals, the clinical trial is reviewing EYP-1901, an investigational sustained delivery anti-vascular endothelial growth factor (anti-VEGF) treatment for wet age-related macular degeneration (wet AMD).
Read More
New human cell line for studying blinding eye disorders discovered by LSU Health Sciences Center
July 27th 2022Scientists at the Louisiana State University Health New Orleans Neuroscience Center of Excellence have developed a new, experimental human cell line from retinal pigment epithelial cells.
Read More
RGX-314 demonstrates DRSS improvements in patients with DME, NPDR
July 15th 2022At ASRS in New York City, Charles Wykoff, MD, presented a talk entitled, “Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy: Phase II ALTITUDE Study.” The trial demonstrated large improvements for patients with diabetic macular edema (DME) and non-proliferative diabetic retinopathy (NPDR), with notable improvements according to the Diabetic Retinopathy Severity Scale (DRSS).
Read More
DME: Faricimab remains durable, effective in 2-year results of YOSEMITE and RHINE trials
July 14th 2022At ASRS in New York City, New York, David Eichenbaum, MD, presented “Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-year Results on the Phase 3 YOSEMITE and RHINE Trials.”
Read More
Delving into the 24-week results for UBX1325 for the treatment of chronic DME, wet AMD
July 14th 2022At ASRS 2022, Raj K. Maturi, MD, presented a talk entitled, “UBX1325, A Novel Senolytic Therapy for Treatment- Experienced Patients With Chronic DME or Wet AMD: 24-Week Results of a Phase 1 Study.”
Read More
The relationship between outer retinal integrity, subretinal fluid may affect treatment outcomes
July 14th 2022At ASRS in New York City, New York, Justis Ehlers, MD, presented a talk entitled, “Higher Order OCT Feature Assessments of the Impact of Fluid Dynamics on Visual Acuity in Neovascular AMD in a Phase III Clinical Trial: The Importance of Outer Retinal Integrity.” Here he discusses the findings.
Read More
Preventing retinal scarring with novel thermogel therapy
July 10th 2022A team of investigators at the Agency for Science, Technology and Research in Singapore have developed a bio-functional thermogel, a type of synthetic polymer, to prevent retinal scarring caused by failed retinal detachment repair surgery.
Read More
Protein levels in eye fluid may predict need for lifelong therapy for macular degeneration
July 9th 2022A team of investigators from Johns Hopkins Medicine say they’ve discovered that levels of a specific protein appears to help accurately predict whether people with the wet form of age-related macular degeneration may need lifelong, frequent eye injections to preserve vision or if they can be safely weaned off the treatments.
Read More